Seeking Alpha

Raptor's PROCYSBI gets EU marketing authorization

  • It's "sell the news" time for Raptor Pharmaceuticals (RPTP -0.9%) apparently, as the shares trade lower after the European Commission approves PROCYSBI as an orphan medicinal product for the treatment of nephropathic cystinosis.
  • The drug got a positive CHMP opinion back in June (which usually bodes well for an EC nod) and was approved by the FDA in April.
  • The aforementioned orphan medicinal product designation gives PROCYSBI 10 years of market exclusivity. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: